Virtus Logo

Our clients

We partner with a range of clients from large pharmaceutical companies to biotechs to assist them in the development of new medicines for respiratory diseases.

Infection rate

The overall infection rate of our current stock of rhinovirus is 82% in asthmatics, COPD and healthy volunteers.

Get in touch

Want to find out more how we can help you develop the next block-buster medicine in asthma or COPD? Get in touch.

Keep Updated With Our Progress

Keep up with the latest results, news and other headlines from Virtus Respiratory Research.

The email address is incorrect
Please agree to our Privacy and Policy
Something went wrong